Theriva Biologics, Inc. (TOVX) · Nov 20, 2026 · Other events
1-for-30 reverse split — 1-for-30 ratio; effective December 1, 2026
Theriva’s reverse split preserves listing access and may aid future financing, but it does not extend the cash runway for VCN-01 trials.
Theriva is a cash-constrained clinical-stage oncology company trying to advance VCN-01 toward larger trials. Its latest 10-Q reported about $8.5 million of cash at September 30, 2026, said current funds extend only into the first quarter of 2027, and said additional financing is needed for future clinical trials. The 1-for-30 split is therefore a capital-markets maneuver, not clinical progress. Theriva will reduce outstanding shares from 45,892,668 to approximately 1,529,756 and begin split-adjusted trading on December 2, 2026. 〔0〕
The move may help preserve exchange access and improve the mechanics of a future financing, but it does not fund the business. The filing explicitly lists maintaining NYSE American compliance and raising capital among the uncertainties surrounding the company. 〔1〕 〔2〕 The authorized share count will also fall proportionally from 350 million to 11. That leaves capacity for issuance, but no financing or partnership is announced here.
The direction was partly telegraphed by Theriva’s financing strain, while the exact action is new. The company had already disclosed a going-concern risk, limited cash for additional VCN-01 trials, and active efforts to secure equity, debt, partnerships, or strategic alternatives. The filing now converts that pressure into a concrete 1-for-30 restructuring, without changing the underlying clinical timetable or adding resources.
Bottom line: This is a meaningful but defensive corporate action: it may keep the financing and listing options open, yet it does not advance VCN-01 or solve Theriva’s funding gap. The business story is slightly weaker because capital pressure has become more visible, but the split itself is not an operational setback.
Financing or partnership before Q1 2027 runway ends
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!